Janus Henderson Group PLC Sells 1,193,417 Shares of Mineralys Therapeutics, Inc. $MLYS

Janus Henderson Group PLC lessened its holdings in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 98.4% in the first quarter, Holdings Channel.com reports. The fund owned 19,848 shares of the company’s stock after selling 1,193,417 shares during the quarter. Janus Henderson Group PLC’s holdings in Mineralys Therapeutics were worth $537,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in MLYS. State Street Corp lifted its stake in shares of Mineralys Therapeutics by 144.4% in the 4th quarter. State Street Corp now owns 3,184,999 shares of the company’s stock valued at $115,584,000 after purchasing an additional 1,881,976 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Mineralys Therapeutics by 6,097.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company’s stock worth $48,089,000 after purchasing an additional 1,303,737 shares during the last quarter. RA Capital Management L.P. grew its stake in shares of Mineralys Therapeutics by 19.1% during the third quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock worth $277,717,000 after purchasing an additional 1,176,470 shares during the period. Orbimed Advisors LLC increased its holdings in Mineralys Therapeutics by 109.4% in the first quarter. Orbimed Advisors LLC now owns 2,052,900 shares of the company’s stock valued at $55,613,000 after purchasing an additional 1,072,500 shares during the last quarter. Finally, Polar Capital Holdings Plc bought a new stake in Mineralys Therapeutics in the third quarter valued at about $40,149,000. Institutional investors own 84.46% of the company’s stock.

Insider Activity at Mineralys Therapeutics

In other news, Director Daphne Karydas sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the transaction, the director owned 6,200 shares in the company, valued at $155,000. This represents a 32.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 104,124 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $25.90, for a total transaction of $2,696,811.60. Following the sale, the insider directly owned 38,400 shares of the company’s stock, valued at $994,560. This represents a 73.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 229,199 shares of company stock worth $5,967,423 over the last ninety days. 18.94% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Jefferies Financial Group restated a “hold” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Wall Street Zen cut Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reiterated a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. TD Cowen assumed coverage on shares of Mineralys Therapeutics in a research note on Monday, April 27th. They set a “buy” rating on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $49.33.

Mineralys Therapeutics Stock Performance

NASDAQ MLYS opened at $27.38 on Tuesday. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of -13.36 and a beta of 0.68. The business has a 50 day simple moving average of $26.41 and a 200 day simple moving average of $27.68. Mineralys Therapeutics, Inc. has a 52-week low of $12.59 and a 52-week high of $47.65.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.